Regenerative Medicine

South Korea's HIGHER Corp. unveils preclinical data for HILO WAVE®, a dual-hyaluronic acid booster that may bypass the inflammatory pathways of competitors.

A new treatment, Junera™, isn't just about smoother skin. It signals a major shift in how the beauty industry operates, blending advanced biostimulation with powerful physician networks.

Revel's new enzyme reverses a hallmark of aging. This isn't just a lab success; it's a strategic move challenging the very definition of 'irreversible'.

A landmark public-private partnership in Vietnam pioneers bioengineered corneas, promising to restore sight to millions and signaling a new era for ASEAN biotech.

A biotech firm just printed kidney and liver tissue in space for the first time, proving orbital manufacturing isn't science fiction, but our medical future.

A biotech's preclinical success in treating miscarriage is just the start. The real story is its strategy of using pregnancy immunology to target cancer.

A new collagen implant is changing ACL treatment, enabling the body to heal itself and significantly reducing the long-term risk of knee osteoarthritis.

MEDIPOST's Phase III trial for knee osteoarthritis isn't just a medical milestone; it's a test case for a faster regulatory path using global data.

Xeltis's bioabsorbable aXess graft hits a major US trial milestone, signaling a strategic shift in renal care away from failing synthetics to living tissue.

A biotech firm is using the ISS to build artificial retinas, bypassing Earth's gravity to create a potential cure for millions facing blindness.

A new study shows Candela's Nordlys laser not only reverses skin aging at a DNA level but may also fight cancer, setting a new bar for the industry.

NurExone's modest C$628k funding isn't a sign of weakness, but a masterclass in biotech survival. It's a strategic play in a cautious market.

Thirty women have received a revolutionary absorbable scaffold that uses their own fat to regenerate breast tissue, promising an end to implant-related risks.

A new milestone in a Parkinson's clinical trial isn't just about the science; it's about building the system to deliver a potential cure to the masses.

Following promising clinical data, biotech firm Immunis unveils a new brand identity, signaling a strategic shift toward multi-pathway biologics for healthy aging.

A new collaboration brings a Swedish-engineered vein therapy to the U.S., offering hope to millions with CVI by replacing diseased tissue with a living graft.

REPROCELL's submission for Stemchymal® offers hope for an incurable disease and highlights Japan's accelerated regulatory path for regenerative medicine.

PetVivo's acquisition of PiezoBioMembrane signals a bold leap from animal care to human health, leveraging advanced biomaterials to chase a larger market.

A new patent for 3D fibroblast spheroids could revolutionize chronic wound treatment, giving FibroBiologics a key edge in the burgeoning biotech market.